Virtu KCG Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Virtu KCG Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,300	Closed	-$389K	–	3797
2015 Q1	$389K	Sell	3,300 -4,600	-58%	-$551K	0.01%	1624
2014 Q4	$939K	Buy	7,900 +3,800	+93%	+$428K	0.02%	1003
2014 Q3	$460K	Sell	4,100 -5,400	-57%	-$514K	0.01%	1791
2014 Q2	$899K	Sell	9,500 -3,000	-24%	-$210K	0.01%	1287
2014 Q1	$884K	Sell	12,500 -17,900	-59%	-$1.42M	0.01%	1362
2013 Q4	$2.26M	Buy	30,400 +1,900	+7%	+$132K	0.02%	582
2013 Q3	$2.16M	Buy	+28,500	New	+$2.27M	0.03%	582

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Virtu KCG Holdings's VRTX Position: Q2 2017 in Review

Virtu KCG Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 1,170% in Q2 2017, buying an estimated $4.13M and bringing the position to 37,212 shares worth $4.8M. The position accounts for 0.13% of the portfolio, ranked #65.

Virtu KCG Holdings first reported a position in VRTX in Q3 2013 and has held it in 14 quarters since. The position peaked at $5.62M in Q1 2016. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Virtu KCG Holdings held 37,212 shares of Vertex Pharmaceuticals worth $4.8M as of Q2 2017.
Virtu KCG Holdings bought 34,283 Vertex Pharmaceuticals shares in Q2 2017, an estimated $4.13M.
Vertex Pharmaceuticals made up 0.13% of Virtu KCG Holdings's portfolio in Q2 2017, its #65 holding.
Virtu KCG Holdings first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 14 quarters since.
Virtu KCG Holdings's Vertex Pharmaceuticals position peaked at $5.62M in Q1 2016.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.